4AJ0 Stock Overview
Operates as an allergy solutions company in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4AJ0 from our risk checks.
ALK-Abelló A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 24.30 |
| 52 Week High | DKK 24.56 |
| 52 Week Low | DKK 9.85 |
| Beta | 0.59 |
| 11 Month Change | 13.45% |
| 3 Month Change | 25.26% |
| 1 Year Change | 117.94% |
| 33 Year Change | 21.93% |
| 5 Year Change | 161.85% |
| Change since IPO | 482.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4AJ0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.08% | 1.5% | 2.8% |
| 1Y | 117.9% | -13.3% | 8.6% |
Return vs Industry: 4AJ0 exceeded the German Pharmaceuticals industry which returned -13.3% over the past year.
Return vs Market: 4AJ0 exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| 4AJ0 volatility | |
|---|---|
| 4AJ0 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4AJ0 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4AJ0's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,806 | Peter Halling | www.alk.net |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
ALK-Abelló A/S Fundamentals Summary
| 4AJ0 fundamental statistics | |
|---|---|
| Market cap | €5.39b |
| Earnings (TTM) | €92.50m |
| Revenue (TTM) | €694.42m |
58.3x
P/E Ratio7.8x
P/S RatioIs 4AJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4AJ0 income statement (TTM) | |
|---|---|
| Revenue | DKK 5.18b |
| Cost of Revenue | DKK 1.89b |
| Gross Profit | DKK 3.29b |
| Other Expenses | DKK 2.60b |
| Earnings | DKK 690.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | 3.12 |
| Gross Margin | 63.44% |
| Net Profit Margin | 13.32% |
| Debt/Equity Ratio | 3.9% |
How did 4AJ0 perform over the long term?
See historical performance and comparison